Seeking Alpha

AstraZeneca (AZN) and Pozen (POZN +7.8%) score EU approval to market their arthritis-pain pill...

AstraZeneca (AZN) and Pozen (POZN +7.8%) score EU approval to market their arthritis-pain pill Vimovo, after the FDA approved the drug in April. Vimovo is seen as a key product for AstraZeneca, which faces the steepest "patent cliff" for patent expiries among European drug makers.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector